Mercer International Stock Surges 45% on C$20 Million Canada Funding 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Add as a preferred source on Google
CAMBRIDGE, Mass., April 09, 2018 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research (AACR 2018), taking place April 14-18, 2018 in Chicago, IL.
Poster 15: “Neoantigen identification using the ATLAS T cell profiling platform highlights the need to empirically define neoantigens”
Vaccines Session 1, Immunology Track
Sunday, April 15, 2018 from 1 pm to 5 pm CDT
Link to abstract
Poster 5718: “Ex vivo ATLAS-identification of neoantigens for personalized cancer immunotherapy in mouse melanoma”
Neoantigens in Cancer Session, Immunology Track
Wednesday, April 18, 2018 from 8 am to 12 pm CDT
Link to abstract
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.
Contact:
Jennifer LaVin
207-360-0473
[email protected]
